At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Market Closed 04-26 16:00:00 EDT
193.33
-1.05
-0.54%
盘后193.00
-0.33-0.17%
19:39 EDT
High195.58
Low189.00
Vol453.35K
Open192.49
D1 Closing194.38
Amplitude3.39%
Mkt Cap4.06B
Tradable Cap2.61B
Total Shares20.99M
T/O87.51M
T/O Rate3.36%
Tradable Shares13.48M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.